Obesity

Obesity is a complex chronic disease that requires long term management. It is among the leading risk factors for several cardio-metabolic diseases such as heart disease, ischemic stroke, liver diseases incl. NASH and type 2 diabetes, as well as for a number of cancers. Obesity continue to rise, and by 2030 it is predicted that one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity (BMI ≥30kg/m2 ) by 2030. The number of people with obesity is on course to double since 2010.

Partnering Interests CardioMetabolic.png

CardioMetabolic Diseases

Read more

Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity

Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
Read more
Healthcare professionals

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Phase 2 Clinical Testing in NASH and Obesity